Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus.
about
Safety and Efficacy Endpoints for Mesenchymal Stromal Cell Therapy in Renal Transplant RecipientsSkin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer?Reviewing 15 years of experience with sirolimusSkin cancer in organ transplant recipients: more than the immune system.The cutting edge of skin cancer in transplant recipients: scientific retreat of international transplant Skin Cancer Collaborative and Skin Cancer in Organ Transplant Patients EuropeMalignant and noninvasive skin tumours in renal transplant recipientsImmune profiling and cancer post transplantationSirolimus effects on cancer incidence after kidney transplantation: a meta-analysis.Update on the long-term complications of renal transplantation.Synergism between mTOR pathway and ultraviolet radiation in the pathogenesis of squamous cell carcinoma and its implication for solid-organ transplant recipients.The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.Skin cancer in kidney transplant recipients.Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients.Human Beta-papillomavirus infection and keratinocyte carcinomas.Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients?Immunological risks of minimization strategies.Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?Renal cancer in kidney transplanted patients.Post-transplantation malignancies: here today, gone tomorrow?Safety of mTOR inhibitors in adult solid organ transplantation.Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas.ACR Appropriateness Criteria(®) Aggressive Nonmelanomatous Skin Cancer of the Head and Neck.Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients.Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients.Squamous cell carcinoma of the skin: Emerging need for novel biomarkersOptimising the use of mTOR inhibitors in renal transplantation.Peripheral natural killer cell and allo-stimulated T-cell function in kidney transplant recipients associate with cancer risk and immunosuppression-related complications.Skin cancer evaluation in transplant patients: a physician opinion survey with recommendations.Epidemiology of keratinocyte carcinomas after organ transplantation.The Effect of Conversion from a Calcineurin Inhibitor to Sirolimus on Skin Cancer Reduction in Post-renal Transplantation Patients.[Tumor and transplantation].The pathogenesis of cutaneous squamous cell carcinoma in organ transplant recipients.Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial.Long-term Change in the Risk of Skin Cancer After Organ Transplantation: A Population-Based Nationwide Cohort Study.Characteristics and prognosis of breast cancer after liver or kidney transplantation.Effects of mammalian target of rapamycin inhibitors on cytokine production and differentiation in keratinocytes.Sirolimus use and cancer incidence among US kidney transplant recipients.Clinically-Relevant Rapamycin Treatment Regimens Enhance CD8+ Effector Memory T Cell Function In The Skin and Allow their Infiltration into Cutaneous Squamous Cell Carcinoma
P2860
Q26799916-FA2F4313-2142-4CAD-B47F-20A26DAA8400Q26851436-1CB3B823-02E1-4D66-85DD-20D3A3C14863Q28080955-63DC60F6-891A-4BD5-A49D-3D4D95B625B5Q33923227-6A4156EF-4793-4B8F-8F7A-CAA713862B61Q34111987-3BBC1EAC-3F5A-48D1-BF85-E436A5BEAAD0Q34268585-17F9055C-C923-47C2-B6FF-31EAB1A53CBAQ35050810-4F19952D-CD24-471A-94D1-BFD828B63CEFQ36051817-CE43C8F8-50BF-4A59-BE4F-49E26856F111Q38104335-EAC25FE1-0188-47DB-8BCE-39C1263D5F0AQ38187197-22AA7153-2665-43F9-B99A-9461AAD1F410Q38195885-D7504067-536F-4928-A768-643E9233897EQ38210273-129389B1-6D12-4A6F-B480-A6CD493020C1Q38210623-4EAA95EE-BF37-40C5-8DD4-98A046894362Q38240647-7EFC5054-E2AB-4810-B344-0ECA0A2FB318Q38328785-F84F0399-5F93-4D93-A0BC-15F8271E7983Q38391150-E52B9BA9-1944-48B5-80D0-FBFE94BAA2D8Q38533271-69FDEAB0-F6EF-4FBF-B4CD-B372E59C5683Q38552310-156FA51D-8B7A-4895-81A0-ACB874B3C5B0Q38611709-EF63D074-C0DB-4E53-B532-EDF23C0806C6Q38669190-85F10F36-3257-4F12-AB90-63566636740EQ38684394-39324D08-7BD7-4D54-8F85-0230251DCFEFQ38704578-3BA3DE9F-D983-443F-9D49-48F61F778D68Q38844500-752583DC-1776-42CF-B2CA-E1902098A69FQ39757990-3AA7FF15-F7E1-4D1D-8BF3-4365C51834D0Q40585796-BB9D1DDE-02DB-4E7A-B81C-D10E7D73D3A9Q41928074-9945DEE6-2F14-446C-928B-3B2174130033Q42413517-EA10146A-9103-4E1B-A1C2-08EF3142C43EQ42470631-00B990CD-B6DE-495B-87FF-C6C4B163B21AQ42516595-8306F48E-BF75-4176-BD3D-363F7918B8F2Q42517229-890A6CA2-6204-4BB7-9061-EC1EF7E9EAA7Q44547715-D7812A73-C136-4C3C-8901-F3AD77532857Q46271884-63182A4B-A738-4310-901A-EC55B4AF9B4EQ47309233-A4CB2B31-3CF5-4AAD-8593-E6BD5AC4B23EQ47739192-07BEC143-9685-4E25-B5E1-C5599D899997Q47979642-6535ACDC-A04D-41D9-87E3-9C077A514729Q53098481-915846DC-C5BA-4B93-97D2-F00E89CC547EQ53226241-F360973D-68E0-41DC-88E5-901FE6932AF3Q58037249-8555F738-38CE-4567-9975-D6DAB5739A7A
P2860
Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Two-year randomized controlled ...... cell carcinomas to sirolimus.
@en
Two-year randomized controlled ...... cell carcinomas to sirolimus.
@nl
type
label
Two-year randomized controlled ...... cell carcinomas to sirolimus.
@en
Two-year randomized controlled ...... cell carcinomas to sirolimus.
@nl
prefLabel
Two-year randomized controlled ...... cell carcinomas to sirolimus.
@en
Two-year randomized controlled ...... cell carcinomas to sirolimus.
@nl
P2093
P356
P1476
Two-year randomized controlled ...... cell carcinomas to sirolimus.
@en
P2093
Andries J Hoitsma
Charlotte M Proby
Jan Nico Bouwes Bavinck
Johan W de Fijter
Judith M Hoogendijk-van den Akker
Paul N Harden
Ron Wolterbeek
P304
P356
10.1200/JCO.2012.45.6376
P407
P577
2013-01-28T00:00:00Z